Reinovax registers Phase 3 trial of PCV24 in adults
The study plans to enroll 1260 Chinese adults aged 18 years and older to evaluate the safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine PCV24. It plans to start on November 24, 2026, with primary completion in October 2027.
Primary source
ClinicalTrials.gov registry record, November 17, 2026
A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
Read the source: A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation